Stuart Green Selected Research

Overactive Urinary Bladder (Overactive Bladder)

1/2019	Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
1/2016	Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
8/2010	A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stuart Green Research Topics

Disease

6	Neoplasms (Cancer) 02/2022 - 04/2015
4	Hypocapnia 02/2022 - 06/2016
4	Nausea 09/2020 - 04/2015
4	Vomiting 09/2020 - 04/2015
3	Overactive Urinary Bladder (Overactive Bladder) 01/2019 - 08/2010
2	Cough 01/2022 - 01/2019
2	Chronic Cough 01/2022 - 01/2019
2	Breast Neoplasms (Breast Cancer) 06/2021 - 07/2016
1	Hyperventilation 02/2022
1	Ganglion Cysts (Ganglion) 01/2018
1	Schizophrenia (Dementia Praecox) 01/2018
1	Cognitive Dysfunction 01/2018
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2017
1	Fatty Liver 01/2017
1	Cardiomyopathies (Cardiomyopathy) 01/2017
1	Alcoholic Cardiomyopathy 01/2017
1	Febrile Neutropenia 04/2015
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2014
1	Mental Disorders (Mental Disorder) 01/2014
1	Inflammation (Inflammations) 02/2011
1	Asthma (Bronchial Asthma) 02/2011
1	Neurofibromatosis type 5 09/2005

Drug/Important Bio-Agent (IBA)

3	Dexamethasone (Maxidex)FDA LinkGeneric 09/2020 - 04/2015
3	Ondansetron (Zofran)FDA LinkGeneric 09/2020 - 04/2015
3	Aprepitant (Emend)FDA Link 10/2018 - 04/2015
2	GefapixantIBA 01/2022 - 01/2019
2	AntiemeticsIBA 09/2020 - 04/2015
2	Tolterodine Tartrate (Detrol)FDA Link 01/2019 - 08/2010
2	N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamideIBA 01/2019 - 01/2016
2	Neurokinin-1 Receptor AntagonistsIBA 04/2015 - 08/2010
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2020
1	AnthracyclinesIBA 09/2020
1	fosaprepitant FDA Link 09/2020
1	Oxygen (Dioxygen)IBA 12/2019
1	Adenosine Triphosphate (ATP)IBA 01/2019
1	Purinergic P2X3 ReceptorsIBA 01/2019
1	Muscarinic AntagonistsIBA 01/2019
1	Narcotics (Narcotic Analgesics)IBA 01/2019
1	Retinaldehyde (Retinal)IBA 01/2018
1	Antipsychotic Agents (Antipsychotics)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Etanercept (Enbrel)FDA Link 01/2017
1	Immunoglobulin G (IgG)IBA 01/2017
1	SteroidsIBA 01/2017
1	Prostaglandins AIBA 01/2017
1	Interleukin-23 (Interleukin 23)IBA 01/2017
1	tildrakizumabIBA 01/2017
1	Adrenergic Agonists (Adrenergic Receptor Agonist)IBA 01/2016
1	EnzymesIBA 02/2011
1	LeukotrienesIBA 02/2011
1	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 08/2010
1	serlopitantIBA 08/2010
1	Nonsense Codon (Nonsense Mutation)IBA 09/2005

Therapy/Procedure

5	Radiotherapy 02/2022 - 06/2016
4	Drug Therapy (Chemotherapy) 09/2020 - 04/2015
3	Therapeutics 12/2020 - 01/2014
2	Mechanical Ventilators (Ventilator) 02/2022 - 06/2016
1	Artificial Respiration (Mechanical Ventilation) 06/2016
1	Patient Care Bundles 01/2014